Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Shareholders' Deficit (Unaudited)

v3.22.4
Condensed Consolidated Statement of Changes in Shareholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Payable [Member]
Subscription Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Mar. 31, 2021 $ 500 $ 56,075 $ 56,649,491 $ 136,000 $ (53,683,268) $ (87,830) $ 3,070,969
Beginning balance, shares at Mar. 31, 2021 5,000,000 607 560,745,180            
Beneficial conversion feature related to the Series E Preferred Shares 3,269,505 3,269,505
Amortization of beneficial conversion feature related to Series E Preferred Shares (817,376) (817,376)
Common stock vested to consultants $ 13 48,738 24,900 73,651
Common stock vested to consultants, shares     125,000            
Net income (loss) (2,562,743) (2,562,743)
Issuance of common stock upon conversion $ 133 421,353 421,486
Issuance of common stock upon conversion, shares     1,329,246            
Conversion of Series B Preferred Shares to common stock $ 314 (314)
Conversion of Series B Preferred Shares to common stock, shares   (262) 3,144,000            
Conversion of Series D PS to common stock $ 43 (43)
Conversion of Series D PS to common stock, shares     428,572            
Exchange of Series D Preferred Shares to Series E Preferred Shares (3,258,189) (3,258,189)
Sale of common shares and warrants for cash, less offering costs and commitment shares $ 3,577 17,273,546 17,277,123
Sale of common shares and warrants for cash, less offering costs and commitment shares, shares     35,772,729            
Exercise of warrants related to the sale of common shares $ 110 10,890 11,000
Exercise of warrants related to the sale of common shares, shares     1,100,000            
Redemption of Series D Preferred shares (2,534,758) (2,534,758)
Common shares to be issued for the acquisition of the non-controlling interest subsidiary's remaining equity (3,087,830) 2,000,000 87,830 (1,000,000)
Common shares to be issued for Patent acquisition 5,000,000 5,000,000
Ending balance, value at Jun. 30, 2021 $ 500 $ 60,265 74,585,336 7,160,900 (62,856,334) 18,950,668
Ending balance, shares at Jun. 30, 2021 5,000,000 345 602,644,727            
Beginning balance, value at Mar. 31, 2021 $ 500 $ 56,075 56,649,491 136,000 (53,683,268) (87,830) 3,070,969
Beginning balance, shares at Mar. 31, 2021 5,000,000 607 560,745,180            
Net income (loss)                 (38,778,923)
Ending balance, value at Dec. 31, 2021 $ 500 $ 64,183 86,808,594 29,524,000 (101,798,974) 14,597,966
Ending balance, shares at Dec. 31, 2021 5,000,000 67 641,722,043            
Beginning balance, value at Jun. 30, 2021 $ 500 $ 60,265 74,585,336 7,160,900 (62,856,334) 18,950,668
Beginning balance, shares at Jun. 30, 2021 5,000,000 345 602,644,727            
Conversion of Series E Preferred Shares to common stock     $ 411 (411)        
Conversion of Series E Preferred Shares to common stock, shares     4,114,286            
Amortization of beneficial conversion feature related to Series E Preferred Shares             (1,341,948)   (1,341,948)
Dividends payable on Preferred Shares             (177,586)   (177,586)
Common stock vested to consultants     $ 6 24,369 24,900       49,275
Common stock vested to consultants, shares     62,500            
Net income (loss) (2,849,635) (2,849,635)
Revision of dividends payable on Series B Preferred Shares (See Note 2)             (182,639)   (182,639)
Common shares issued for Technical and Equipment Rights Agreement         4,762,376       4,762,376
Ending balance, value at Sep. 30, 2021 $ 500 $ 60,683 74,609,294 11,948,176 (67,408,142) 19,210,511
Ending balance, shares at Sep. 30, 2021 5,000,000 345 606,821,513            
Conversion of Series E Preferred Shares to common stock $ 411 2,879,589 2,880,000
Conversion of Series E Preferred Shares to common stock, shares     4,114,286            
Beneficial conversion feature related to the Series E Preferred Shares 169,714 169,714
Amortization of beneficial conversion feature related to Series E Preferred Shares (831,543) (831,543)
Accretion of Series E Preferred Shares (80,167) (80,167)
Dividends payable on Preferred Shares (112,577) (112,577)
Common stock vested to consultants $ 21 99,054 (49,800) 49,275
Common stock vested to consultants, shares     112,500            
Net income (loss) (33,366,545) (33,366,545)
Conversion of Series B Preferred Shares to common stock $ 334 (334) (334)
Conversion of Series B Preferred Shares to common stock, shares   (278) 3,336,000            
Common shares issued for Technical and Equipment Rights Agreement $ 2,673 11,759,706 (11,762,376)
Common shares issued for Technical and Equipment Rights Agreement, shares     26,732,673            
Common stock issued to consultants $ 43 158,285 158,328
Common stock issued to consultants, shares     430,071            
Common stock vested to employees $ 18 68,286 68,304
Common stock vested to employees, shares     175,000            
Reclassification of warrants to liability (2,935,000) (2,935,000)
Common stock to be issued for legal settlement to NSH shareholders 29,388,000 29,388,000
Ending balance, value at Dec. 31, 2021 $ 500 $ 64,183 86,808,594 29,524,000 (101,798,974) 14,597,966
Ending balance, shares at Dec. 31, 2021 5,000,000 67 641,722,043            
Beginning balance, value at Mar. 31, 2022 $ 500 $ 67,500 96,701,607 20,132,650 (150,036,023) (33,133,766)
Beginning balance, shares at Mar. 31, 2022 5,000,000 674,644,124            
Common stock issued for legal settlement to NSH shareholders $ 6,112 19,311,486 (19,317,598)
Common stock issued for legal settlement to NSH shareholders, shares     61,154,136            
Conversion of Series E Preferred Shares to common stock $ 454 839,546 840,000
Conversion of Series E Preferred Shares to common stock, shares     4,537,240            
Beneficial conversion feature related to the Series E Preferred Shares 99,000 (99,000)
Amortization of beneficial conversion feature related to Series E Preferred Shares (42,500) (42,500)
Accretion of Series E Preferred Shares (278,500) (278,500)
Dividends payable on Preferred Shares (102,227) (102,227)
Common stock issued in business agreement $ 25 56,225 (56,250)
Common stock issued in business agreement ,shares     250,000            
Common stock vested to consultants $ 6 24,369 24,375
Common stock vested to consultants, shares                
Net income (loss)             (2,200,176) (2,200,176)
Ending balance, value at Jun. 30, 2022 $ 500 $ 74,097 117,032,233 815,052 (56,250) (152,758,426) (34,892,794)
Ending balance, shares at Jun. 30, 2022 5,000,000 740,585,500            
Beginning balance, value at Mar. 31, 2022 $ 500 $ 67,500 96,701,607 20,132,650 (150,036,023) (33,133,766)
Beginning balance, shares at Mar. 31, 2022 5,000,000 674,644,124            
Net income (loss)                 (11,552,820)
Increase of 10% in Series E Preferred Shares to one holder based on certain rights                 156,000
Ending balance, value at Dec. 31, 2022 $ 500 $ 76,894 119,464,471 662,767 (56,250) (163,037,985) (42,889,603)
Ending balance, shares at Dec. 31, 2022 5,000,000 768,561,129            
Beginning balance, value at Jun. 30, 2022 $ 500 $ 74,097 117,032,233 815,052 (56,250) (152,758,426) (34,892,794)
Beginning balance, shares at Jun. 30, 2022 5,000,000 740,585,500            
Common stock issued for legal settlement to NSH shareholders $ 40 127,646 (127,686)
Common stock issued for legal settlement to NSH shareholders, shares     404,067            
Amortization of beneficial conversion feature related to Series E Preferred Shares (42,500) (42,500)
Accretion of Series E Preferred Shares (278,500) (278,500)
Dividends payable on Preferred Shares (55,427) (55,427)
Common stock issued in business agreement $ 25 25,975   26,000
Common stock issued in business agreement ,shares     250,000            
Common stock vested to consultants $ 6 24,369 24,375
Common stock vested to consultants, shares     62,500            
Net income (loss)             (24,528,345) (24,528,345)
Conversion of Series E Preferred Shares to common stock $ 992 827,008 (108,000) 720,000
Conversion of Series E Preferred Shares to common stock, shares     9,920,887            
Increase of 10% in Series E Preferred Shares to one holder based on certain rights             (156,000)   (156,000)
Common stock issued from shares payable $ 10 24,590 (24,600)  
Common stock issued from shares payable, shares     100,000            
Ending balance, value at Sep. 30, 2022 $ 500 $ 75,170 118,061,820 662,767 (56,250) (177,927,198) (59,183,191)
Ending balance, shares at Sep. 30, 2022 5,000,000 751,322,954            
Amortization of beneficial conversion feature related to Series E Preferred Shares (28,048) (28,048)
Accretion of Series E Preferred Shares (198,333) (198,333)
Dividends payable on Preferred Shares (60,107) (60,107)
Common stock vested to consultants $ 6 24,369 24,375
Common stock vested to consultants, shares     62,500            
Net income (loss)             15,175,701 15,175,701
Issuance of common shares under financing agreement     $ 1,718 1,378,282         1,380,000
Issuance of common shares under financing agreement, shares     17,175,675            
Ending balance, value at Dec. 31, 2022 $ 500 $ 76,894 $ 119,464,471 $ 662,767 $ (56,250) $ (163,037,985) $ (42,889,603)
Ending balance, shares at Dec. 31, 2022 5,000,000 768,561,129